JD Health International Inc. reported that on 28 May 2026 it bought back 2.53 million ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 38.04 and HKD 40.30, for a total consideration of HKD 96.92 million. All repurchased shares are slated for cancellation.

Including this latest transaction, JD Health has repurchased 15.95 million shares since the 20 June 2025 general mandate took effect, equivalent to 0.50 % of the company’s issued share capital as at the mandate date. The mandate authorises buybacks of up to 320.01 million shares, leaving approximately 304.07 million shares, or 99.50 % of the authorisation, still available.

Issued share capital remained unchanged at 3.21 billion shares between 27 May 2026 and 28 May 2026. Shares bought back from 15 May to 28 May 2026 but not yet cancelled also total 15.95 million.

Under Main Board Rule 10.06(3)(a), JD Health is subject to a moratorium on issuing new shares until 27 June 2026 following the latest repurchase. All repurchases were executed in compliance with Hong Kong Stock Exchange regulations, and the company confirmed no material changes to the April 2025 explanatory statement that accompanied the repurchase mandate.